Saline (0.9%, sterile, for infusion)
DrugSailine as control
NCT Number: NCT07351500
Severe community-acquired pneumonia caused by influenza virus (hereafter referred to as severe influenza pneumonia) is a major etiology of community-acquired pneumonia leading to acute respiratory failure and ICU admission. It can rapidly progress to profound hypoxemia, acute respiratory distress syndrome (ARDS), and multiple organ dysfunction, and remains associated with substantial mortality. Although antiviral therapy-typically neuraminidase inhibitors-and well-established organ-support strategies are currently available, outcomes in a subset of critically ill patients remain poor despite antiviral and supportive care alone, with ICU mortality reported to be as high as 20-30%. Therefore, identifying effective adjunctive interventions beyond standard care to further reduce mortality in severe influenza pneumonia is of great clinical importance for improving outcomes in critically ill patients and alleviating the burden on families and society.
However, the use of systemic corticosteroids in influenza-associated community-acquired pneumonia (CAP) has long been highly controversial. Multiple studies have suggested that corticosteroid therapy may increase mortality among patients with H1N1 influenza. During the early phase of the COVID-19 pandemic, treatment strategies drew on this evidence and generally advised caution regarding corticosteroid use; subsequently, randomized controlled trials (RCTs) such as RECOVERY and REMAP-CAP demonstrated that low-dose corticosteroids (e.g., dexamethasone 6 mg/day) reduce mortality in patients with pneumonia requiring oxygen therapy. Recently, the U.S. Centers for Disease Control and Prevention (CDC) has emphasized the urgent need for RCTs evaluating low- to moderate-dose corticosteroids or other immunomodulatory agents to clarify their role in the management of influenza-associated CAP. Collectively, these observations underscore the urgency of pathogen-directed anti-inflammatory strategies for CAP-associated acute respiratory failure.
Accordingly, we plan to conduct an adaptive, randomized, open-label, controlled trial to evaluate the efficacy and safety of adjunctive corticosteroid regimens at different doses, in addition to early standard supportive care (including guideline-concordant antiviral therapy and organ support), for reducing mortality in patients with severe influenza pneumonia.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 3
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(i) Requirement for endotracheal intubation and mechanical ventilation;
(ii) Septic shock requiring vasopressor therapy after adequate fluid resuscitation.
-Or simultaneously fulfilling three of the minor criteria:
(i) Respiratory rate ≥ 30 breaths/min;
(ii) PaO₂/FiO₂ ≤ 250 mmHg;
(iii) Multilobar infiltrates;
(iv) Altered mental status and/or disorientation;
(v) Blood urea nitrogen ≥ 20 mg/dL (7.12 mmol/L);
(vi) Leukopenia (white blood cell count < 4 × 10⁹/L);
(vii) Thrombocytopenia (platelet count < 100 × 10⁹/L);
(viii) Hypothermia (core temperature < 36 °C);
(ix) Hypotension (systolic blood pressure < 90 mmHg) requiring aggressive fluid resuscitation.
Exclusion criteria
Sailine as control
Methylprednisolone 0.5mg/kg ivgtt qd
Methylprednisolone 1.0mg/kg ivgtt qd
Time frame: 28 days from inclusion
Qingyuan Zhan
Other
An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Severe Influenza Community-Acquired Pneumonia in Adults
Acronym: CAPSTONE-IFV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07416266
Acute Bronchitis, Acute Exacerbation Chronic Obstructive Pulmonary Disease
View Trial DetailsNCT07703514
Infections, Influenza
Baltimore, Maryland, United States
View Trial DetailsNCT07599449
COVID - 19, COVID-19
Paris, France
View Trial DetailsNCT07610967
COVID-19 Respiratory Infection, Infections
View Trial Details